Immunocore Holdings Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
493
- Stock Symbol
-
6YG
- Share Price
-
$28.26
- (As of Thursday Closing)
Immunocore Holdings General Information
Description
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Contact Information
Website
www.immunocore.comCorporate Office
- 92 Park Drive
- Milton Park, Oxon
- Abingdon OX14 4RY
- England, United Kingdom
Corporate Office
- 92 Park Drive
- Milton Park, Oxon
- Abingdon OX14 4RY
- England, United Kingdom
Immunocore Holdings Timeline
Immunocore Holdings Stock Performance
As of 17-Apr-2025, Immunocore Holdings’s stock price is $28.26. Its current market cap is $1.4B with 49.3M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $28.26 | $27.33 | $22.84 - $61.91 | $1.4B | 49.3M | -$1.02 |
Immunocore Holdings Financials Summary
As of 31-Dec-2024, Immunocore Holdings has a trailing 12-month revenue of $310M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,055,748 | 1,055,748 | 3,019,480 | 2,428,958 |
| Revenue | 310,202 | 310,202 | 249,428 | 174,361 |
| EBITDA | (55,507) | (55,507) | (69,632) | (33,895) |
| Net Income | (51,087) | (51,087) | (55,287) | (52,543) |
| Total Assets | 1,009,506 | 1,009,506 | 597,001 | 526,762 |
| Total Debt | 432,722 | 432,722 | 85,010 | 81,449 |
Immunocore Holdings Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immunocore Holdings Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Immunocore Holdings Comparisons
Industry
Financing
Details
Immunocore Holdings Competitors (70)
One of Immunocore Holdings’s 70 competitors is CureVac, a Formerly VC-backed company based in Tubingen, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CureVac | Formerly VC-backed | Tubingen, Germany | ||||
| Aldeyra Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Coherus Biosciences | Formerly VC-backed | Redwood City, CA | ||||
| BioNTech | Formerly VC-backed | Mainz, Germany |
Immunocore Holdings Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Immunocore Holdings Patents
Immunocore Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202418912-D0 | Specific binding molecules | Pending | 20-Dec-2024 | ||
| GB-202411647-D0 | Method | Pending | 07-Aug-2024 | ||
| GB-202406837-D0 | Screening methods | Pending | 14-May-2024 | ||
| GB-202320012-D0 | Bispecific molecules | Pending | 22-Dec-2023 | ||
| GB-202315181-D0 | Peptide-hla binding molecules | Inactive | 03-Oct-2023 | C07K16/2833 |
Immunocore Holdings Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Immunocore Holdings Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Immunocore Holdings Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Immunocore Ireland | Dublin, Ireland | 2018 |
Immunocore Holdings FAQs
-
When was Immunocore Holdings founded?
Immunocore Holdings was founded in 2007.
-
Where is Immunocore Holdings headquartered?
Immunocore Holdings is headquartered in Abingdon, United Kingdom.
-
What is the size of Immunocore Holdings?
Immunocore Holdings has 493 total employees.
-
What industry is Immunocore Holdings in?
Immunocore Holdings’s primary industry is Biotechnology.
-
Is Immunocore Holdings a private or public company?
Immunocore Holdings is a Public company.
-
What is Immunocore Holdings’s stock symbol?
The ticker symbol for Immunocore Holdings is 6YG.
-
What is the current stock price of Immunocore Holdings?
As of 17-Apr-2025 the stock price of Immunocore Holdings is $28.26.
-
What is the current market cap of Immunocore Holdings?
The current market capitalization of Immunocore Holdings is $1.4B.
-
What is Immunocore Holdings’s current revenue?
The trailing twelve month revenue for Immunocore Holdings is $310M.
-
Who are Immunocore Holdings’s competitors?
CureVac, Aldeyra Therapeutics, Inovio Pharmaceuticals, Coherus Biosciences, and BioNTech are some of the 70 competitors of Immunocore Holdings.
-
What is Immunocore Holdings’s annual earnings per share (EPS)?
Immunocore Holdings’s EPS for 12 months was -$1.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
